Difference between revisions of "Apalutamide (Erleada)"
m |
m |
||
| Line 25: | Line 25: | ||
*2019-12-12: New indication | *2019-12-12: New indication | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| + | *2019-03-26: New approval for the treatment of non-metastatic, castration-resistant [[prostate cancer]]. | ||
*2020-05-29: new indication for the treatment of metastatic [[prostate cancer]]. | *2020-05-29: new indication for the treatment of metastatic [[prostate cancer]]. | ||
==Also known as== | ==Also known as== | ||
| Line 43: | Line 44: | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
[[Category:Health Canada approved in 2018]] | [[Category:Health Canada approved in 2018]] | ||
| + | [[Category:PMDA approved in 2019]] | ||
Revision as of 20:46, 8 June 2023
General information
Class/mechanism: Antiandrogen; androgen receptor inhibitor (ARI). Apalutamide competitively inhibits activity mediated by the androgen receptor (AR) by binding directly to the AR ligand-binding domain, nuclear translocation, DNA binding, and AR-mediated transcription. A metabolite of apalutamide,
N-desmethyl apalutamide, also exhibits some AR inhibiting activity, about 1/3 that of apalutamide.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Apalutamide (Erleada) package insert[1]
- Apalutamide (Erleada) patient drug information (Chemocare)[4]
- Apalutamide (Erleada) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2018-02-14: FDA approved for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). (Based on SPARTAN)
- 2019-09-17: Approved for patients with metastatic castration-sensitive prostate cancer (mCSPC). (Based on TITANprostate)
History of changes in EMA indication
- 2019-01-14: Initial marketing authorization as Erleada.
History of changes in Health Canada indication
- 2018-07-03: Initial notice of compliance for the treatment of patients with non-metastatic castration-resistant prostate cancer at high risk of developing metastases.
- 2019-12-12: New indication
History of changes in PMDA indication
- 2019-03-26: New approval for the treatment of non-metastatic, castration-resistant prostate cancer.
- 2020-05-29: new indication for the treatment of metastatic prostate cancer.
Also known as
- Code name: ARN-509
- Brand name: Erleada